A phase 2 repeat dosing clinical trial of SB-509 [Sangamo BioSciences] in subjects with diabetic neuropathy.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 509 (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Sangamo BioSciences
- 30 Jun 2010 Results reported at 70th Annual Scientific Sessions of the American Diabetes Association (ADA), according to a Sangamo media release.
- 29 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History